Comparative Pharmacology
Head-to-head clinical analysis: METAHYDRIN versus TRICHLORMETHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METAHYDRIN versus TRICHLORMETHIAZIDE.
METAHYDRIN vs TRICHLORMETHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metahydrin (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing excretion of water, sodium, chloride, and potassium.
Inhibits sodium-chloride symporter in distal convoluted tubule, increasing excretion of sodium, chloride, and water.
Oral, 50-100 mg once daily. Maximum 200 mg/day.
2-4 mg orally once daily; maximum 4 mg/day.
None Documented
None Documented
18-30 hours (clinically relevant for once-daily dosing in hypertension; prolonged in renal impairment)
Clinical Note
moderateTrichlormethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digoxin."
Clinical Note
moderateTrichlormethiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digitoxin."
Clinical Note
moderateTrichlormethiazide + Deslanoside
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Deslanoside."
Clinical Note
moderateTerminal elimination half-life is approximately 2-6 hours (average 3.5 h); clinical context: short half-life necessitates once or twice daily dosing for sustained diuresis.
Renal: 30% (fecal: 70% as unabsorbed drug, primarily biliary elimination; <1% unchanged in urine)
Primarily renal (tubular secretion); ~70% excreted unchanged in urine; minor biliary/fecal (<10% total).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic
Trichlormethiazide + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Acetyldigitoxin."